Table 1. Patient Clinical Characteristics.
| Characteristic | No. (%) | P valuea | No. (%) | P valuea | ||||
|---|---|---|---|---|---|---|---|---|
| All RP (n = 3175) | All EBRT (n = 1830) | All EBRT + BT (n = 999) | Optimal RP (n = 1600) | Optimal EBRT (n = 879) | Optimal EBRT + BT (n = 461) | |||
| Follow-up, median (IQR), y | 4.24 (2.57-7.29) | 8.17 (5.05-11.67) | 8.70 (5.96-11.92) | <.001 | 4.59 (2.79-7.59) | 8.85 (5.75-11.67) | 9.31 (7.04-12.74) | <.001 |
| Age, median (IQR), y | 64.4 (58.5-69.1) | 70.0 (63.7-75.6) | 67.7 (62.1-72.7) | <.001 | 64.5 (58.6-68.8) | 69.4 (63.1-75.2) | 67.1 (61.2-72.1) | <.001 |
| Initial PSA, median (IQR), ng/mL | 11.2 (5.8-25.2) | 15.0 (7.2-30.1) | 18.6 (8.1-30.3) | <.001 | 12 (6.2-27.4) | 15.2 (7.2-32.8) | 22.3 (11.4-34.6) | <.001 |
| Biopsy Gleason grade group | ||||||||
| 1 | 124 (3.9) | 63 (3.4) | 74 (7.5) | <.001 | 104 (6.5) | 32 (3.6) | 47 (10.5) | <.001 |
| 2 | 229 (7.2) | 215 (11.8) | 89 (8.9) | 185 (11.6) | 99 (11.3) | 47 (10.5) | ||
| 3 | 264 (8.3) | 183 (10.0) | 161 (16.3) | 177 (11.1) | 91 (10.4) | 100 (22.3) | ||
| 4 | 1254 (39.6) | 839 (45.9) | 357 (36.2) | 960 (60.3) | 382 (43.5) | 137 (30.5) | ||
| 5 | 1297 (40.9) | 527 (28.8) | 304 (30.9) | 167 (10.5) | 274 (31.2) | 118 (26.3) | ||
| Clinical tumor category | ||||||||
| 1c | 1407 (45.8) | 459 (25.4) | 210 (21.1) | <.001 | 736 (47.5) | 177 (20.4) | 85 (18.5) | <.001 |
| 2a | 553 (17.4) | 268 (14.8) | 88 (8.8) | 294 (18.4) | 122 (13.9) | 37 (8.1) | ||
| 2b | 409 (13.3) | 252 (13.9) | 133 (13.4) | 185 (11.9) | 122 (13.9) | 38 (8.3) | ||
| 2c | 230 (7.5) | 176 (9.7) | 123 (12.3) | 87 (5.6) | 87 (9.9) | 68 (14.8) | ||
| 3a | 317 (10.3) | 344 (18.8) | 307 (30.8) | 163 (10.5) | 185 (21.3) | 169 (36.8) | ||
| 3b | 133 (4.3) | 238 (13.2) | 120 (12.0) | 75 (4.8) | 136 (15.7) | 57 (12.4) | ||
| 4 | 21 (0.7) | 70 (3.9) | 15 (1.5) | 9 (0.6) | 40 (4.6) | 5 (1.1) | ||
Abbreviations: BT, brachytherapy boost; EBRT, external beam radiotherapy; IQR, interquartile range; PSA, prostate-specific antigen; RP, radical prostatectomy.
SI conversion factor: To convert PSA to micrograms per liter, multiply by 1.
a
Continuous variables across treatments are compared using the Kruskal-Wallis test. The association between treatment and categorical variables are assessed using χ2 test of association.